Protagonist Therapeutics, Inc cotiza a 144.88 USD y tiene una capitalización bursátil de $9.4B. En los últimos 12 meses ha facturado $282M con un margen de flujo de caja libre del 121.9%. Cotiza a 71.8 veces su flujo de caja libre (P/FCF) y a un PER de 113.1. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $2.29 | $0.05 | $-0.69 |
| Estimado | $2.62 | $1.93 | $-0.65 | $-0.54 |
| Sorpresa | — | +18.7% | +107.7% | -27.8% |
| Métrica | PTGX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -343.6% | -38.6% | -305.0% |
| Net Margin | -282.8% | -33.6% | -249.3% |
| FCF Margin | 121.9% | -13.9% | +135.7% |
| ROE | -21.2% | -40.4% | +19.2% |
| ROA | -19.5% | -32.0% | +12.5% |
| Current Ratio | 12.71 | 2.84 | +9.87 |
| Debt / Equity | — | 0.28 | — |